Overview

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Status:
Completed

Trial end date:
2019-08-20

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.

Phase:

Phase 2

Details

Lead Sponsor:

Cyclerion Therapeutics
Ironwood Pharmaceuticals, Inc.

Treatments:

Praliciguat